DocDollars

Acerus Pharmaceuticals Corporation

Canada · Reporting entity ID 100000736811

Total reported 2019–2025
$944K
#1,328 of 2,960 reporting companies — 0% of all reported industry payments
$423K in general payments across 8,396 records, plus $522K in research funding across 145 records.

How it breaks down

General payments $422,640
Research funding $521,722

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Acerus Pharmaceuticals Corporation reported $944K to US doctors and teaching hospitals from 2019 to 2025, ranking #1,328 of 2,960 reporting companies. 55% of that was research funding and 45% general payments such as consulting, speaking, food and travel. 8,396 general payment records and 145 research records were filed.

Common questions about Acerus Pharmaceuticals Corporation

How much has Acerus Pharmaceuticals Corporation paid US doctors?

Acerus Pharmaceuticals Corporation reported $944,362 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $422,640 in general payments, $521,722 in research funding.

How does Acerus Pharmaceuticals Corporation rank among drug and device companies?

It ranks #1,328 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Acerus Pharmaceuticals Corporation mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.